semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Vaccine for Meningococcal Disease Male or non-pregnant female 18 through 85 years of age, both inclusive, at the time of study vaccine administration. 2. Provide written informed consent. 3. The subject is resident of the study area and is willing to comply with study protocol requirements, including availability for all scheduled visits of the study. 4. Healthy, as determined by medical history and clinical assessment of the investigator. 5. Female subjects of childbearing potential must have a negative urine pregnancy test within 24 hours prior to study vaccine administration  Acute illness, at the time of study vaccine administration (once acute illness is resolved, if appropriate, as per investigator assessment, subject will be re-revaluated for eligibility). 2. History of any meningococcal vaccine administration. 3. Current or previous, confirmed or suspected disease caused by N. meningitidis. 4. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 90 days prior to vaccination. 5. History of severe allergic reactions after previous vaccinations or hypersensitivity to any study vaccine component including tetanus, diphtheria and diphtheria toxoid (CRM197)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acute Hypercapnic Respiratory Failure All patients admitted in Assiut University Hospital and Assiut Police Hospital with acute hypercapnic respiratory failure due to COPD and Obesity hypoventilation syndrome (OHS) indicated for conventional NIV. Patients who failed on low pressure NIV will be shifted to high pressure NIV with any of these conditions: 1. PH <7.30 or less than admission level. 2. RR > 35b/m or more than admission level. 3. SpO2 < 88%  (4) 1. Age <18 years. 2. Excessive amount of respiratory secretions or weak cough. 3. Upper airway obstruction. 4. Recent oral, facial or cranial trauma or surgery. 5. Sever abdominal distension. 6. Active upper gastrointestinal bleeding. 7. Cardiac or respiratory arrest. 8. PH<7.25. 9. Arterial oxygen tension /fraction of inspired oxygen (PaO2 / FiO2) <150mmHg
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ICU Acquired Weakness Rehabilitation Aged above 18 The hemodynamics are stable < heart rate less than 120 beats/min < systolic blood pressure < 200mmHg < mean arterial pressure < 120mmHg Do not increase the dose of vasopressor for at least 2 hours Intracranial pressure was stable and there is no seizure within 24 hours The breathing condition is stable the oxygen satiety of the patient's finger vein is ≥88% the breathing frequency < 35 times/min  Pregnancy Acute myocardial infarction (ami)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 16.0-90.0,  COVID-19 Pneumonia Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two 1. Severe respiratory failure [respiratory rate> 25 <35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)] 2. Requiring invasive mechanical ventilation  Patients with a viral infection other than COVID-19
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  COVID-19 Men or women aged 18-75 years. 2. The presence of COVID-19 infection, confirmed by PCR testing 3. The presence of the COVID-19 pneumonia pattern on the chest HRCT with a damage to more than 25% of the lung parenchyma 4. Morning fever ≥ 38.0 °C over the last three days 5. CRP blood level ≥ 50 mg / ml or ferritin blood level ≥ 600 μg / ml 6. A signed informed consent  Respiratory index ≤200 2. Contraindications for the transfusion of donor immune plasma or history of prior reactions to blood transfusions 3. Mechanical ventilation 4. The presence of chronic lung diseases with chronic respiratory failure. 5. The need for home continuous oxygen therapy before the onset of current disease. 6. Serum creatinine level higher than 150 μmol / l 7. Pregnancy or breastfeeding
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 22.0-64.0,  AS A total of 40 consecutive male AS patients were invited to participate in this study. Patients were recruited from Outpatient Clinic of Rheumatology, Mansoura University Hospital, between January and September 2019. AS was diagnosed according to modified New York criteria. During the same period, 40 age-matched healthy males were invited to participate in the study as a control group  patients or controls with thyroid or parathyroid disorders, presence of chronic renal or liver disease, and use of any medication that could potentially interfere with bone metabolism including bisphosphonates, teriparatide, anticonvulsants, anticoagulants, calcium and corticosteroids. None of the participants was using vitamin D supplements
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 19.0-85.0,  Sepsis Microcirculation Sepsis: a life-threatening organ dysfunction (defined as an acute change in total Sequential Organ Failure Assessment (SOFA) score > 2 points consequent to infection) caused by a dysregulated host response to infection Sepsis shock : a subset of sepsis with persisting hypotension requiring vasopressors to maintain the mean arterial pressure > 65 mmHg and having a serum lactate level > 2 mmol/L after fluid resuscitation  Non-survivors in the first 24 hours from sepsis Sepsis post-acute cardiac arrest Pregnancy Younger than 18 years old Acute Respiratory Distress Syndrome (ARDS) with the ratio of arterial oxygen partial pressure (mmHg) to fractional inspired oxygen (PaO2/ FiO2) < 200) Advanced malignancy Untreated and unstable acute coronary syndrome History of myocardial infarction with severe left ventricular dysfunction. (Ejection fraction < 20 %) Inoperable valvular and coronary disease Significant right-left cardiac shunt
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  SARS-CoV 2 Hospitalisation-Associated Infection Male of female aged 18 or over Patients with at least one of the following diagnostic allowing to suspect an infection by the virus SARS-CoV Clinical picture with fever, and/or exertional dyspnea, and/or PO2 < 80mmHg And/or chest scanner very suggestive or compatible with a COVID-19 infection And/or a RT-PCR positive result already known Hospitalized patient in a COVID-19 medical unit, based on one or several diagnostic elements described Possibility to collect blood and urine samples as described in protocol Patients informed of the study, having understood it, and who didn't oppose to their participation  Clinical condition justifying immediate hospitalization in the intensive care unit During the initial patient management, an immediate need of oxygen requiring intubation and/or oxygen supply greater than 6 liters / minute Patients under legal protection Pregnant or breastfeeding women
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID 19 signed inform consent COVID 19 with the mild and severe course. The diagnosis could be made with positive polymerase chain reaction (PCR) (International Statistical Classification (ICD-10) code U07.1) and/or virus pneumonia in computer tomography (ICD 10 code U07.2) 5. Lung exposure on CT more than 25% 6. Sp02 without supportive oxygen ≤ 93% 7. C-reactive protein > 60 mg/l or elevation of C reactive protein 3 times in 8-14 days after first symptoms  pregnancy and breastfeeding hypersensitivity to Spironolactone hypersensitivity to Bromhexine Known liver failure Glomerular filtration rate <20 ml/ min physician judgment that the patient will need mechanical ventilation in 24 hours other indications for Spironolactone Active cancer
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsed/Refractory B-cell Lymphomas Diffuse Large B Cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma (MZL) Mantle Cell Lymphoma Small Lymphocytic Lymphoma (SLL) Primary Mediastinal Large B Cell Lymphoma Transformed Follicular Lymphoma Patients with relapsed / refractory previously treated B cell malignancies (according to the World Health Organization classification; 2017) Chemotherapy-refractory disease Patients must have received adequate prior therapy including at least two lines of prior therapies including anthracycline-containing chemotherapy, anti-CD20 (cluster of differentiation antigen 20) therapies and/or Brutton's tyrosine kinase (BTK) inhibitors Patients treated with prior CD19 targeted molecules (e.g., Blincyto) must have confirmed CD19+ disease Patients must be ineligible for allogeneic stem cell transplant (SCT) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 Estimated life expectancy of ≥ 12 weeks from the first day of SWI019 dose administered Willing to undergo pre and post-treatment core needle biopsy Adequate hematological, renal, pulmonary, cardiac, and liver function  Patients diagnosed with disease histologies including pediatric lymphomas/leukemias, Burkitt lymphoma, lymphoplasmacytic lymphomas, monoclonal gammopathy of undetermined significance (MGUS), T-cell histiocyte large B cell lymphoma Pregnant or lactating women Active bacterial, viral, and fungal infections History of allogeneic stem cell transplantation Treatment with any prior CD19 or CD20 CAR-T Patients receiving live (attenuated) vaccines within 4 weeks of screening visit or need for live vaccine on study Patients with known active central nervous system (CNS) disease. Patients with prior CNS disease that has been effectively treated may be eligible History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction, unstable angina or other significant cardiac disease within 6 months of screening Involvement of cardiac tissue by lymphoma Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 12.0-100.0,  Critical COVID-19 With Respiratory Failure Critical COVID-19 with Respiratory Failure  Patients who are eligible for enrollment in RLF-100_001 are excluded from this protocol and live within 50 miles of a study site for NCT04311697 cannot be enrolled unless already admitted to an ICU and ineligible for transfer Mean Arterial Pressure < 65 mm Hg with use of pressor per ICU protocol Irreversible condition (other than COVID-19) with projected fatal course ECMO Chemotherapy-induced neutropenia (granulocyte count <1000/mm3) Cardiogenic shock; congestive heart failure NYHA Class 3 or 4 Liquid Diarrhea more than 3x/day; defined as more than 3 non-bloody watery stools within a 24-hour period, requiring additional fluid and electrolyte supplementation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID 19 COVID-19 positive patients (confirmed by PCR) with cytokine storm state who will not improve after two doses of tocilizumab of failure (resistance) to tocilizumab: 1. Persistent high IL-6 and CRP. 2. Persistent worsening of respiratory symptoms ( dyspnea, tachypnea, increased oxygen (O2) requirements or even need for mechanical ventilation). 3. Partial arterial pressure of oxygen to fractional inspired concentration of oxygen (PaO2/FiO2) ratio < 150. 4. Persistent fever (˃38.5°C) despite normal procalcitonin level  Refractory septic shock: ( It is defined according to surviving sepsis campaign as the presence of hypotension with end organ dysfunction requiring high dose vasopressor support often greater than 0.5 µg/kg/min norepinephrine or equivalent)
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID 19 Adults (˃18 years) COVID-19 positive patients (confirmed by PCR) Moderate infection ( pneumonia ± leucopenia or lymphopenia )  Severe or life threatening COVID infection: Severe disease is defined as: dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, and/or lung infiltrates > 50% within 24 to 48 hours. Life threatening disease is defined as: respiratory failure, septic shock, and/or multiple organ dysfunction or failure  Pregnant or lactating females Participation in any investigational clinical study, other than observational, within the past 30 days; or plans to participate in such a study at any time from the day of enrollment until 30 days post-treatment in the current study Allergy or hypersensitivity to sirolimus Taking immunosuppressive drugs Glomerular filtration rate (GFR) < 30 ml/min by CKD-EPI equation liver cirrhosis  Decompensated heart failure known active tuberculosis (TB) or history of incompletely treated TB Uncontrolled systemic bacterial or fungal infections
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 Age at least 18 years 2. Laboratory confirmed diagnosis of infection with SARS-CoV-2 3. Admitted to the hospital for the treatment of COVID-19 complications 4. Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease 5. Informed consent provided by the patient or healthcare proxy 6. Severe COVID-19 is defined by one or more of the following dyspnea respiratory frequency ≥ 30/min blood oxygen saturation ≤ 93% partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 lung infiltrates > 50% within 24 to 48 hours Life-threatening COVID-19 is defined as one or more of the following respiratory failure/mechanical ventilation septic shock multiple organ dysfunction or failure